$9.04
-1.73-16.06%
Last update: Nov 5, 4:00 PM
DiaMedica Therapeutics Inc (DMAC) Stock Price, Quote, News & History
DMACNASDAQ
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.
You can purchase shares of DiaMedica Therapeutics (NASDAQ:DMAC) through any online brokerage.
Other companies in DiaMedica Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
DiaMedica Therapeutics has a consensus price target of $12.67.
The stock price for DiaMedica Therapeutics (NASDAQ: DMAC) is $9.04 last updated November 5, 2026 at 4:00 PM EST.
There are no upcoming dividends for DiaMedica Therapeutics.
DiaMedica Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for DiaMedica Therapeutics.
DiaMedica Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main...
